Profile

Steffan Nawrocki

Medicine

Full Page

Overview

Research

Collaboration(17)

Page 1 of 4

Grants(10)

Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
Active·2023·$53.9K / $1.1M·
External
Co-Investigator (COI)
mitochondrial dysfunction, cardiotoxicity, integrated stress response, ponatinib, activation
University of Arizona Cancer Center - Cancer Center Support Grant
Active·2022·$0 / $12.6M·
External
Key Personnel (KP)
cancer research, medical oncology, grants, cancer treatment, supportive care
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
Active·2022·$704.4K / $1.4M·
External
Principal Investigator (PI)
lysosomes, renal disease, pathogenesis, therapeutics, drug discovery
In Vivo Anti-Cancer Activity of CB-5339 In Combination with PARP Inhibitor Olaparib in the MX-1 Breast Cancer Model
2022·$19.3K / $38.6K·
External
Co-Investigator (COI)
cancer, parp inhibitor, breast cancer, in vivo, combination therapy
Metabolic Reprogramming and Pulmonary Vascular Disease in Congenital Heart Disease
2020·$24.2K / $2.4M·
External
Co-Investigator (COI)
metabolic reprogramming, pulmonary vascular disease, congenital heart disease, metabolism, cardiovascular disease

Page 1 of 2

Publications(73)

Recent

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

2023

immune profiling, oncolytic virus therapy, multiple myeloma, single-cell analysis, microenvironment

Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?

2023

immuno-oncology, urothelial carcinoma, t-cell blockade, cancer immunotherapy, metastatic cancer

Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity

2023

neddylation, cisplatin, nephrotoxicity, targeted therapy, drug-induced toxicity

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy

2020

autophagy, renal cell carcinoma, therapy, therapeutic targeting, cancer

Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

2020

cancer, virotherapy, epigenetics, drug resistance, oncolytic viruses

Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance

2020

autophagy, tumorigenesis, drug resistance, cellular mechanisms, cancer therapy

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance

2020

autophagy, cancer progression, drug resistance, cellular mechanisms, therapeutic targets

ABCG2 Overexpression Contributes to Pevonedistat Resistance

2020

cancer, drug resistance, abcg2, gene expression, pevonedistat

Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia

2020

mutation analysis, clinical phenotypes, therapy response, myeloid neoplasia, hotspot mutations

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity

2019

cancer, drug development, epigenetics, targeted therapy, protein regulation

People

Profile

Steffan Nawrocki

Collaboration(17)

Todd Vanderah

Benjamin Lee

Anne Cress

Wei Wang

Jason Wertheim

Grants(10)

Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity

University of Arizona Cancer Center - Cancer Center Support Grant

Targeting Lysosomal Vulnerabilities in Renal Pathogenesis

In Vivo Anti-Cancer Activity of CB-5339 In Combination with PARP Inhibitor Olaparib in the MX-1 Breast Cancer Model

Metabolic Reprogramming and Pulmonary Vascular Disease in Congenital Heart Disease

Publications(73)

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?

Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy

Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance

ABCG2 Overexpression Contributes to Pevonedistat Resistance

Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity